Rumor on the Street: Teva to Buy Barr Pharmaceuticals?
A post today on the Pharmalot blog suggests that Israeli generic manufacturer Teva is in talks to acquire US-based Barr Pharmaceuticals for $7.0 -7.5$ billion. Barr’s present market cap is approximately $5.0 billion.
The acquisition would make sense for Teva to broaden its reach into the generic and branded generic markets in the US. Also, Barr recently acquired PLIVA which has active research programs on biosimilars and is currently selling its version of EPO in Croatia and other parts of Eastern Europe.
Teva has been trying to get into the biosimilar/follow-on biologics market for the past eight years or so. The company previously bought several early stage biogenerics manufacturers but have yet to advance their plans to formally enter the biosimilar/follow-on biologics market. This may be the opportunity that Teva has been looking for!
Check back for updates.
Until next time…
Good Luck and Good Job Hunting!!!!!!
As much as I do enjoy the frivolity of rumor & innuendo, I am not sure this one will come off as suggested. However, if it does, it certainly speaks to this (now obvious) trend of consolidation in the pharmaceutical sector.
While there are always deals to be made, it seems there has been a fire lit under the desk of most VP/Business Development in the past 1-2 months.
To M&A or not to M&A, that is the question.